您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报（医学版） ›› 2017, Vol. 55 ›› Issue (2): 38-44.doi: 10.6040/j.issn.1671-7554.0.2016.1350

• 放射性粒子植入治疗肿瘤专题 • 上一篇    下一篇

CT引导放射性125I粒子植入治疗23例浅表淋巴结转移瘤

林琦,张颖,戴建建,徐瑞彩,杨琦,耿宝成,韩明勇   

  1. 山东大学附属省立医院东院保健综合(肿瘤)科, 山东 济南 250014
  • 收稿日期:2016-10-20 出版日期:2017-02-10 发布日期:2017-02-10
  • 通讯作者: 韩明勇. E-mail:hanmingyong@sina.com E-mail:hanmingyong@sina.com
  • 基金资助:
    国家自然科学基金(81272351)

CT-guided 125I seed brachytherapy for superficial lymph node metastases: a report of 23 cases

LIN Qi, ZHANG Ying, DAI Jianjian, XU Ruicai, YANG Qi, GENG Baocheng, HAN Mingyong   

  1. Department of Health Oncology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250014, Shandong, China
  • Received:2016-10-20 Online:2017-02-10 Published:2017-02-10

PDF (PC)

292

摘要： 目的 探讨放射性125I粒子植入治疗浅表淋巴结转移瘤的技术方法、近期疗效及临床意义。 方法 对2014年12月至2016年6月放射性125I粒子植入治疗的23例浅表淋巴结转移瘤的患者进行回顾性分析。所有患者术前应用治疗计划系统(TPS)制定植入计划,根据术前计划在CT引导下行浅表淋巴结转移瘤125I粒子植入术,术后行质量验证。分别于术后1、3、6、9、12个月复查CT,进行临床疗效及并发症评估。 结果 对23例患者、28个靶区病灶进行了治疗,术后1、3、6、9、12个月的局部控制率分别为84.6%、82.4%、81.2%、83.3%和85.7%。中位随访时间为9个月( 1~16个月),生存15例,死亡8例。靶区病灶的中位局部控制时间为12个月(95% CI: 7.4, 16.5),而中位无进展生存时间为3个月(95% CI: 0.3, 5.7),P=0.194。术后出现急性皮肤放疗反应Ⅰ/Ⅱ级6例,无其他并发症和不良反应。 结论 125I粒子植入治疗浅表淋巴结转移瘤,方法可行,近期疗效可靠,安全性较高,是局部治疗有效方法之一。

关键词: 浅表淋巴结转移瘤, 局部控制率, 125I粒子, 并发症

Abstract: Objective To evaluate the efficacy and complications of CT-guided permanent 125I seed brachytherapy in patients with the superficial lymph node metastases. Methods Clinical data of 23 patients with 28 superficial lymph node metastases who underwent CT-guided 125I seed brachytherapy during Dec. 2014 and Jun. 2016 were retrospectively reviewed. Brachytherapy was preplanned for all patients using a 3-dimensional radiation therapy planning system. With CT guidance, 125I seed was placed into the metastases. Dosimetry verification was performed immediately after operation. Efficacy and complications were evaluated 1, 3, 6, 9 and 12 months postoperatively. Results The median local control rate of 1, 3, 6, 9 and 12 months was 84.6%, 82.4%, 81.2%, 83.3% and 85.7%, respectively. The median follow-up was 9 months(1-16 months), during which 8 patients died and 15 survived. The local control time was 12 months(95% CI: 7.4, 16.5), the median progression-free-survival(PFS)was 3 months(95% CI: 0.3, 5.7), P=0.194. No major complications occurred during or after brachytherapy except for Ⅰ/Ⅱ acute skin radioreaction in 6 cases. Conclusion CT-guided 125I seed brachytherapy is a safe and effective treatment for superficial lymph node metastases with few complications.

Key words: Complications, Local control rate, Superficial lymph node metastases, 125I seed

中图分类号: 

  • R730.5
[1] 汤钊猷. 现代肿瘤学[M]. 上海: 上海医科大学出版社, 1993: 102.
[2] 谷铣之, 殷蔚伯, 刘泰福, 等. 肿瘤放射治疗学[M]. 北京: 北京医科大学、中国协和医科大学联合出版社, 1991: 143.
[3] 王俊杰, 修典荣, 冉维强. 放射性粒子组织间近距离治疗肿瘤[M]. 北京: 北京大学医学出版社, 2014: 162-174.
[4] Huo X, Wang H, Yang J, et al. Effectiveness and safety of CT-guided 125I seed brachytherapy for postoperative locoregional recurrence in patients with none-small cell lung cancer[J]. Brachytherapy, 2016, 15(3): 370-380.
[5] 房菲菲, 张颖, 林琦, 等. CT引导放射性125I粒子植入治疗转移性肝癌的临床疗效[J]. 山东大学学报(医学版), 2016, 54. doi:10.6040/j.issn.16717554.0.2016.1106. FANG Feifei, ZHANG Ying, LIN Qi, et al. Clinical efficacy of CT guided 125I seed brachytherapy in the treatment of metastatic hepatic carcinoma[J]. Journal of Shandong University(Health Sciences), 2016, 54. doi:10.6040/j.issn.16717554.0.2016.1106.
[6] Lin L, Wang J, Jiang Y, et al. Interstitial 125I seed implantation for cervical lymph node recurrence after multimodal treatment of thoracic esophageal squamous cell carcinoma[J]. Technol Cancer Res Treat, 2015, 14(2): 201-207.
[7] Gao F, Li C, Gu Y, et al. CT-guided 125I brachytherapy for mediastinal metastatic lymph nodes recurrence from esophageal carcinoma: effectiveness and safety in 16 patients[J]. Eur J Radiol, 2013, 82(2): 70-75.
[8] 高飞, 顾仰葵, 黄金华, 等. CT引导下125Ⅰ近距离治疗肝癌腹膜后转移性淋巴结的临床价值[J]. 中华医学杂志, 2013, 93(27): 2155-2157. GAO Fei, GU Yangkui, HUANG Jinhua, et al. Clinical value of CT-guided 125I brachytherapy for retroperitoneal metastatic lymph node from PHC[J]. National Medical Journal of China, 2013, 93(27): 2155-2157.
[9] 蒲德利, 廖江荣, 彭刚. 放射性125I粒子植入近距离放射治疗18例口腔癌的疗效观察[J]. 介入放射学杂志, 2013, 22: 851-853. PU Deli, LIAO Jiangrong, PENG Gang. The therapeutic effect of brachytherapy with125I seed implantation for oral cancer: observation of 18 cases[J]. J Intervent Radiol, 2013, 22: 851-853.
[10] Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: revised RECIST guideline(version1.1)[J]. Eur J Cancer, 2009, 45(2):228-247.
[11] Cox JD, Stetz J, Pajak TF. Toxicity criteria of the radiation therapy oncology group(RTOG)and the european organization for research and treatment of cancer(EORTC)[J]. Int J Radiat Oncol Biol Phys, 1995, 31(5): 1341-1346.
[12] Yao L, Jiang Y, Jiang P, et al. CT-guided permanent 125I seed interstitial brachytherapy for recurrent retroperitoneal lymph node metastases after external beam radiotherapy[J]. Brachytherapy, 2015, 14(5): 662-669.
[13] 柴树德, 郑广钧. 胸部肿瘤放射性粒子治疗学[M]. 北京: 人民卫生出版社, 2012: 17-29.
[14] Zhang T, Lu M, Peng S, et al. CT-guided implantation of radioactive 125I seed in advanced non-small-cell lung cancer after failure of first-line chemotherapy[J]. J Cancer Res Clin Oncol, 2014, 140(8): 1383-1390.
[15] Li J, Xie Q, Wang W, et al. CT-guided implantation of 125I seeds(permanent brachytherapy)for metastatic tumors of the hepatic portal system: effectiveness and safety in 13 patients[J]. Brachytherapy, 2016, 15(2): 224-230.
[16] Li W, Guan J, Yang L, et al. Iodine-125 brachytherapy improved overall survival of patients with inoperable stage Ⅲ/Ⅳ non-small cell lung cancer versus the conventional radiotherapy[J]. Med Oncol, 2015, 32(1): 395. doi: 10.1007/s12032-014-0395-8.
[17] Aronowitz JN.Introduction of transperineal image-guided prostate brachytherapy[J]. Int J Radiat Oncol Biol Phys, 2014, 89(4): 907-915.
[18] Zuber S, Wei S, Baaske D, et al. Iodine-125 seed brachytherapy for early stage prostate cancer: a single-institution review[J]. Radiat Oncol, 2015, 10: 49. doi: 10.1186/s13014-015-0349-0.
[19] Zhang L, Lu J, Wang Z, et al. Clinical efficacy of computed tomography-guided iodine-125 seed implantation therapy in patients with advanced spinal metastatic tumors[J]. Onco Targets Ther, 2015, 9: 7-12. doi: 10.2147/OTT.S95410.
[20] Zhang L, Chen LH, Wang J, et al. CT-guided radioactive 125I seed implantation treatment of multiple pulmonary metastases of hepatocellular carcinoma[J]. Clin Radiol, 2014, 69(6): 624-629.
[21] Xiang Z, Mo Z, Li G, et al. 125I brachytherapy in the palliation of painful bone metastases from lung cancer after failure or rejection of conventional treatments[J]. Oncotarget, 2016, 7(14): 18384-18393.
[22] Gobardhan PD, de Wall LL, van der Laan L, et al. The role of radioactive iodine-125 seed localization in breast-conserving therapy following neoadjuvant chemotherapy[J]. Ann Oncol, 2013, 24(3): 668-673.
[23] 张忠涛, 隋庆兰. 吴善良, 等. CT导引植入125I放射性粒子治疗颈部淋巴结转移癌的临床应用[J]. 介入放射学杂志, 2015, 24(10): 881-884. ZHANG Zhongtao, SUI Qinglan, WU Shanliang, et al. Clinical application of CT-guided 125I radioactive seed implantation in treating cervical lymph node metastasis[J]. J Intervent Radiol, 2015, 24(10): 881-884.
[24] 王娟, 孙美玲, 张宏涛, 等. 外放疗后复发颈部淋巴结转移癌17例125I粒子植入治疗的初步疗效[J]. 介入放射学杂志, 2014, 23(9): 784-787. WANG Juan, SUN Meiling, ZHANG Hongtao, et al. Radioactive 125I seed implantation for the treatment of recurrent cervical lymphatic metastases after radiotherapy: preliminary results in 17 cases[J]. J Intervent Radiol, 2014, 23(9): 784-787.
[25] 张颖, 林琦, 袁苑, 等. 3D打印个体化模板联合CT引导125I粒子植入治疗恶性肿瘤质量评价[J]. 山东大学学报(医学版), 2016, 54(11): 44-50. ZHANG Ying, LIN Qi, YUAN Yuan, et al. The feasibility of 3D print individual template combined with CT guided 125I seed implantation for malignant tumor[J]. Journal of Shandong University(Health Sciences), 2016, 54(11): 44-50.
[26] 张颖, 林琦, 韩明勇, 等. 3D打印个体化模板联合CT引导治疗胸壁肿瘤1例[J]. 山东大学学报(医学版), 2016, 54(4): 94-96.
[27] 王俊杰. 3D打印技术与精准粒子植入治疗学[M]. 北京: 北京大学医学出版社, 2016: 54-63.
[28] 江萍, 马月, 王俊杰, 等. 超声引导放射性125I粒子植入治疗头颈部复发肿瘤[J]. 北京大学学报(医学版), 2012, 44(2): 291-294. JIANG Ping, MA Yue, WANG Junjie, et al. Ultrasound guided implantation of radioactive 125I seeds for treatment of recurrent head and neck carcinomas[J]. Journal of Peking University(Health Sciences), 2012, 44(2): 291-294.
[1] 郭志华,赵大庆,邢园,王薇,梁乐平,杨静,赵倩倩. Ⅰ期端端吻合术治疗重度颈段气管狭窄临床分析[J]. 山东大学学报 (医学版), 2020, 1(7): 72-76.
[2] 林琦,张颖,袁苑,戴建建,徐瑞彩,杨琦,耿宝成,韩明勇. 肾上腺转移瘤放射性125I粒子植入治疗后胃穿孔1例[J]. 山东大学学报（医学版）, 2017, 55(7): 124-129.
[3] 曹倩倩,姜玉华,李玉亮,杨瑞杰,刘路,张喜乐,王俊杰. 放射性125I粒子植入与外放疗治疗颈椎转移瘤剂量学对比分析[J]. 山东大学学报（医学版）, 2017, 55(7): 55-60.
[4] 张振堂,杨洋,韩福俊,陈向华,季晓康,王永超,王淑康,孙苑潆,李敏,陈亚飞,王丽,薛付忠,刘言训. 基于社区2型糖尿病患者的心脑血管事件5年风险预测模型[J]. 山东大学学报（医学版）, 2017, 55(6): 108-113.
[5] 卢晔,崔会芳,陈旭君,黄溢华,吴奕群,黄建隆,陈辉民,熊贤俊,陈明红. 冷冻技术在呼吸介入治疗中的应用进展及其并发症防治浅析[J]. 山东大学学报（医学版）, 2017, 55(4): 19-22.
[6] 王娟,张宏涛,高贞,底学敏,王泽阳. 腹部肿瘤放射性粒子植入并发症处理及预防[J]. 山东大学学报（医学版）, 2017, 55(2): 8-13.
[7] 戴建建,袁冰,张颖,林琦,袁苑,韩明勇. CT引导下125I粒子植入治疗Ⅲ期非小细胞肺癌疗效与并发症的临床观察[J]. 山东大学学报（医学版）, 2017, 55(2): 32-37.
[8] 许玉军,柳明,何祥萌,李成利. 1.0T开放型磁共振引导经皮穿刺125I放射性粒子植入治疗晚期胰腺癌[J]. 山东大学学报（医学版）, 2017, 55(2): 21-25.
[9] 张颖,林琦,袁苑,戴建建,耿宝成,徐瑞彩,刘亚坤,韩明勇. 3D打印个体化模板联合CT引导125I粒子植入治疗肿瘤术前术后剂量学比较[J]. 山东大学学报（医学版）, 2017, 55(2): 45-49.
[10] 李扬,何闯,陈玉潇,杨丽,李良山,李廷源,黄学全. 放射性125I粒子植入近距离治疗长骨转移瘤的临床疗效[J]. 山东大学学报（医学版）, 2017, 55(2): 50-54.
[11] 袁苑,张颖,林琦,戴建建,李冉冉,徐瑞彩,杨琦,耿宝成,韩猛,韩明勇. 125I粒子植入术后应用透明质酸钠凝胶皮下注射保护皮肤1例[J]. 山东大学学报（医学版）, 2017, 55(11): 89-92.
[12] 梁飞,张文龙,张军,许崇恩,邹承伟. 不停跳冠脉旁路移植术后心肌酶明显升高的相关因素及早期并发症[J]. 山东大学学报（医学版）, 2017, 55(10): 71-75.
[13] 王丽丽,霍彬,王磊,汪浩,侯定坤,霍小东,王金焕,臧立,曹强,柴树德,王海涛. 亚肺叶切除联合125I粒子植入治疗早期肺癌有效性的Meta分析与系统评价[J]. 山东大学学报（医学版）, 2017, 55(10): 76-83.
[14] 张颖,林琦,袁苑,戴建建,耿宝成,徐瑞彩,刘亚坤,韩明勇. 3D打印个体化模板联合CT引导125I粒子植入治疗胸壁转移瘤1例[J]. 山东大学学报（医学版）, 2016, 54(4): 94-96.
[15] 房菲菲,张颖,林琦,袁苑,戴建建,徐瑞彩,耿宝成,韩明勇. CT引导放射性125I粒子植入治疗转移性肝癌的临床疗效[J]. 山东大学学报（医学版）, 2016, 54(12): 53-57.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发